IL2 and neuroblastoma: Combinational usage of Dinutuximab and interleukin 2 (IL-2), granulosa cell macrophage colony-stimulating factor (GM-CSF), and isotretinoin have been found to significantly increase the survival of patients diagnosed with high-risk neuroblastoma (14, 15).